This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jun 13, 2024
•
10 min read
BMS still has an M&A appetite, Ultragenyx has some bone-building Ph2/3 results, Eli Lilly's Alzheimer's approval could be good news for rivals Biogen and Eisai too, Foresite Capital raises a $900M life science fund, and Pfizer signs a discovery pact with ProFound Therapeutics in search of the next great obesity med
Jun 12, 2024
9 min read
Syntis Bio to take on GLP-1 giants, Ipsen's new FDA approval, an ADC and an "ADC-like" company both raise millions, cancer patient groups like AstraZeneca, and Pfizer takes an M&A break
Jun 11, 2024
8 min read
Eli Lilly gets full support from FDA advisory panel, GSK's RSV vaccine gets a label expansion, Moderna’s flu/covid combo passes Ph3, Amber Therapeutics raises $100M, Alumis plans an IPO, and the FDA gets curious about AI
Jun 10, 2024
Geron lands first FDA approval after 34 years, Abbvie & Calico join FDA rare disease pilot, Rapport Therapeutics upsized IPO to $154M, and Eli Lilly could secure Alzheimer's throne
Jun 8, 2024
6 min read
🧬 Winners, Losers, and Upcoming Earnings Calls
Jun 7, 2024
Boehringer & Zealand Pharma Ph2 NASH data "unintentionally" published early, Seres Therapeutics sells a commercial asset to stay afloat, Abbvie's $10.1B ImmunoGen acquisition delivers Ph2 win, Nucleus RadioPharma fundraise, and Structure Therapeutics hopes to ride the data wave to a $476M stock sale
Jun 6, 2024
Amgen's Ph3 rare disease success from $27.8B Horizon acquisition, Annexon sells $125M in common stock, Telix Pharmaceuticals plans $200M IPO, and Finland's taking no chances with bird flu.
Jun 5, 2024
Lykos gets an FDA advisory thumbs down, BridgeBio & Viking Therapeutics deliver positive results but their stocks drop anyway, AstraZeneca's "armoured" CAR-T, and Summit cashes in $200M from an institutional investor.
Jun 4, 2024
Eli Lilly buys an ALS asset, Caribou touts partial HLA matching for allogeneic cell therapies, Jazz has "unprecedented" long-term data, and Merck discusses a post-Keytruda future.
Jun 3, 2024
GSK's ADC comeback story, Sanofi & Regeneron receive mixed signals, Moderna gets RSV vaccine approval, and an MDMA treatment lands FDA scrutiny.
Jun 2, 2024
May 31, 2024
11 min read
Merck gets beaten at it’s own game, BMS lands another CAR-T indication, Otsuka dives into digital therapeutics, and "hub-and-spoke" biotech raises $73M.
